Radius Health v. Orbicular Pharmaceutical: Federal Circuit Appeal Voluntarily Dismissed
Radius Health, Inc. brought a five-patent infringement appeal to the Federal Circuit over its Tymlos® (abaloparatide) osteoporosis therapy, asserting patents US8148333B2, US10996208B2, USRE049444E, US8748382B2, and US11782041B2 against Indian generics company Orbicular Pharmaceutical. The parties agreed to dismiss the proceeding under Fed. R. App. P. 42(b) just 70 days after filing, with each side bearing its own costs.
Five-patent Tymlos® appeal ends in 70-day agreed dismissal
Radius Health, Inc., the developer and patent holder of Tymlos® (abaloparatide), filed this appeal at the Court of Appeals for the Federal Circuit on 15 September 2025, asserting five patents — US8148333B2, US10996208B2, USRE049444E, US8748382B2, and US11782041B2 — against Orbicular Pharmaceutical Technologies Private Ltd., an Indian generic pharmaceutical manufacturer. The underlying action concerned infringement of patents covering abaloparatide, a synthetic peptide used in the treatment of osteoporosis in postmenopausal women at high risk of fracture.
The Federal Circuit proceeding was terminated on 24 November 2025 by mutual agreement of the parties under Federal Rule of Appellate Procedure 42(b). The order records that the proceeding is ‘DISMISSED’ and that ‘each side shall bear their own costs.’ The basis of termination is recorded as voluntary dismissal. The public record does not specify whether the dismissal was with or without prejudice — a distinction that carries significant consequences for Radius Health’s ability to re-assert these patents against Orbicular in future proceedings.
The 70-day lifespan of this appeal is notably short and suggests the parties reached an agreement — whether a settlement, licence, or other commercial resolution — rapidly after filing. The absence of a cost award to either side is consistent with a negotiated resolution rather than a procedural default. What drove the resolution, whether any licensing terms were agreed, and whether the underlying district court dispute remains live are not discernible from the public appellate record alone.
Filing to Voluntary dismissal in 70 days
70-day appeal lifespan — well below the typical Federal Circuit resolution timeline of 12–18 months
Voluntarily dismissed: what the agreed dismissal means for both parties
Fed. R. App. P. 42(b) dismissal: what it means
Federal Rule of Appellate Procedure 42(b) permits parties to jointly stipulate to dismiss an appeal. The court gives effect to that agreement without reaching the merits. This is a procedural endpoint, not a substantive ruling on patent validity or infringement. It signals that the parties resolved their dispute outside the court’s adjudicatory process — but the public record does not confirm whether the dismissal was with or without prejudice to refiling.
Procedural — no merits rulingWith or without prejudice? The record is silent
A voluntary dismissal ‘with prejudice’ permanently bars the dismissing party from re-asserting the same claims; ‘without prejudice’ preserves that right. The order in this case states only that the proceeding is ‘DISMISSED’ under Rule 42(b) and that costs are split — it does not specify either form of prejudice. This ambiguity is commercially material: if dismissed without prejudice, Radius Health could potentially re-assert its five Tymlos® patents against Orbicular at the district court level or in a new ANDA proceeding.
Prejudice status: unconfirmedPatent holder exits appeal with five patents intact
Radius Health retains ownership of all five abaloparatide patents. No adverse appellate ruling was entered. However, without a favourable merits decision, Radius Health has not secured a judicial determination of infringement or validity against Orbicular. If the dismissal was ‘with prejudice,’ Radius Health may face obstacles re-asserting these specific claims. The cost-neutral outcome is consistent with a negotiated resolution rather than a concession.
No adverse ruling — patents intactRapid resolution signals possible commercial arrangement
A 70-day voluntary dismissal at the Federal Circuit level — with no cost award — is a pattern typically consistent with a settlement, licence, or supply agreement reached after filing. For the abaloparatide market, this outcome leaves the patent landscape unresolved judicially: no claim of US8148333B2 or its companion patents has been adjudicated invalid or non-infringed. Other generic entrants facing similar ANDA-related Tymlos® litigation should monitor any public licence disclosures from either party.
Possible licence or settlementFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | RADIUS HEALTH, INC. | Company | Pharmaceutical innovator and holder of five Tymlos® (abaloparatide) patentsSearch in Eureka ↗ |
| Defendant | ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LTD. | Company | Indian generic pharmaceutical manufacturer — Orbicular Pharmaceutical Technologies Private Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Geoffrey Donovan Biegler | Attorney | Counsel for RADIUS HEALTH, INC.Search in Eureka ↗ |
| Plaintiff counsel | Heidi Lyn Keefe | Attorney | Counsel for RADIUS HEALTH, INC.Search in Eureka ↗ |
| Plaintiff counsel | W. Chad Shear | Attorney | Counsel for RADIUS HEALTH, INC.Search in Eureka ↗ |
| Plaintiff law firm | Cooley LLP | Law Firm | Representing RADIUS HEALTH, INC.Search in Eureka ↗ |
| Defendant counsel | Alan Henry Pollack | Attorney | Counsel for ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LTD.Search in Eureka ↗ |
| Defendant law firm | Windels Marx Lane & Mittendorf, LLP | Law Firm | Representing ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LTD.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order’s phrasing — ‘The parties having so agreed’ — confirms this was a consensual exit rather than a unilateral or court-initiated termination. The Rule 42(b) citation is the standard appellate mechanism for stipulated dismissal and carries no merits implication. Notably, the order is silent on prejudice, which is atypical for a negotiated dismissal and may reflect deliberate ambiguity agreed by the parties. The cost-neutral provision reinforces the interpretation of a balanced negotiated outcome rather than capitulation by either side.
US8148333B2, US10996208B2, USRE049444E, US8748382B2 & US11782041B2 — Abaloparatide
The five asserted patents protect different aspects of abaloparatide — a synthetic peptide analogue of parathyroid hormone-related protein (PTHrP) marketed as Tymlos® for postmenopausal osteoporosis. The portfolio spans application families filed between 2009 (US12/311418, priority for US8148333B2) and 2021 (US17/220891, leading to US11782041B2), reflecting a decade-long prosecution strategy. The inclusion of reissue patent USRE049444E — which corrects or broadens claims of an original grant — indicates active portfolio maintenance to sustain competitive exclusivity.
For the osteoporosis treatment sector, this five-patent bundle represents a multi-layered barrier to generic entry. Competitors targeting Tymlos® through ANDA filings must independently evaluate validity and infringement risk across all five patent families — compositions, methods of use, dosing regimens, and formulation claims. The 2023-issued US11782041B2 extends the effective patent protection timeline significantly, and no judicial invalidity ruling has been entered against any of these patents as of the case closure date.
Should you run an FTO analysis against Radius Health’s abaloparatide patent portfolio?
Any pharmaceutical company, contract manufacturer, or CDMO developing or supplying abaloparatide — whether for generic, biosimilar-adjacent, or novel formulation purposes — faces material exposure from this five-patent portfolio. With patents expiring on different timelines across distinct claim families, a single FTO assessment is insufficient. R&D teams working on PTHrP analogue peptides for osteoporosis should map each patent independently against their specific composition, formulation, and method of administration.
PatSnap Eureka’s FTO Search Agent enables rapid, AI-assisted claim mapping across all five abaloparatide patents simultaneously. Eureka can surface related prosecution history, identify cited prior art, flag post-grant proceedings, and monitor for continuation filings from Radius Health. For teams preparing ANDA submissions or evaluating licensing requirements, Eureka’s portfolio monitoring tools provide early warning of new assertions — before litigation is filed.
Run a freedom-to-operate analysis on US8148333B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit pharmaceutical patent appeals involving ANDA and peptide patents
Federal Circuit cases involving voluntary dismissal of pharmaceutical patent appeals — particularly those covering peptide-based osteoporosis therapies — provide direct comparators for assessing Radius Health’s litigation strategy and abaloparatide market dynamics.
What this case signals for the abaloparatide and osteoporosis IP landscape
A rapid Federal Circuit exit in a five-patent pharmaceutical case rarely signals weakness — more often it signals commercial resolution.
No judicial invalidity finding — all five Tymlos® patents remain enforceable
Because the Federal Circuit dismissed the proceeding without reaching the merits, no court has ruled any of the five abaloparatide patents invalid or not infringed. For Radius Health, this preserves full enforcement optionality. For generic developers, these patents remain live risks requiring FTO analysis before any ANDA filing targeting Tymlos®.
Cost-neutrality and speed point toward negotiated resolution
Mutual cost-bearing and a 70-day lifespan are hallmarks of an agreed commercial resolution rather than a default or procedural collapse. Whether that resolution is a licence, supply deal, or co-existence agreement is not public — but the pattern suggests Orbicular’s path to market may have been addressed outside court, which has direct implications for competitive entry timing.
RADIUS v ORBICULAR — key questions answered
The Federal Circuit appeal was voluntarily dismissed by agreement of the parties under Fed. R. App. P. 42(b) on 24 November 2025, just 70 days after filing. No merits ruling was entered on any of the five asserted abaloparatide patents. Each side was ordered to bear its own appellate costs.
Radius Health asserted five patents: US8148333B2, US10996208B2, USRE049444E, US8748382B2, and US11782041B2. All relate to abaloparatide, the active ingredient in Tymlos®, covering peptide compositions, pharmaceutical formulations, and methods of treatment for postmenopausal osteoporosis.
The Federal Circuit order does not specify. It states only that the proceeding is ‘DISMISSED’ under Rule 42(b) and that each side bears its own costs. The public appellate record is silent on prejudice status, which is a material ambiguity for assessing whether Radius Health can reassert these claims against Orbicular in future proceedings.
A Rule 42(b) dismissal is purely procedural — the court makes no ruling on patent validity, claim scope, or infringement. The patents remain in full force. The dismissal eliminates the specific appellate proceeding but does not extinguish the underlying patent rights or necessarily bar future enforcement against the same or different parties.
Tymlos® is Radius Health’s brand name for abaloparatide, a synthetic peptide analogue of parathyroid hormone-related protein approved by the FDA for treating osteoporosis in postmenopausal women at high risk of fracture. As a branded pharmaceutical with a substantial patent portfolio, it is a target for ANDA filings by generic manufacturers seeking market entry — making patent enforcement litigation a standard competitive dynamic in this category.
PatSnap Eureka searches patents and litigation data to answer instantly.